Pulmonary arterial hypertension: Bridging the gap between ef?cacy, quality of life, and cost-effectiveness

Formulary

Volumn 45, Issue 6, 2010, Pages 190-199

  Gandhi, Raj ^a   Baker, Nicholas ^b   Shek, Allen ^b   Yeh, Johnathan ^c   Bishop, Dale ^c  

^a Health Plan of San Joaquin   (United States)

^b Health Plan of San Joaquin   (United States)

^c Health Plan of San Joaquin ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; AMLODIPINE; ANTICOAGULANT AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; NIFEDIPINE; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; TADALAFIL; UNIPROST; VASODILATOR AGENT;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; CLINICAL TRIAL; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; HUMAN; OPTIMAL DRUG DOSE; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; SURVIVAL RATE;

EID: 77958458700     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007;131:1917-1928.
2. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53:1573-1619.
3. Garin MC, Clark, L, Chumney E, Simpson KN, Highland KB. Cost-utility of treatments for pulmonary arterial hypertension. A Markov State Transition Decision Analysis Model. Clin Drug Investig. 2009;29:635-646.
4. Hoeper MM. De nition, classi cation, and epidemiology of pulmonary arterial hypertension. Semin Respir Crit Care Med. 2009;30:369-375.
5. Hyduk A, Croft JB, Ayala C, Zheng K, Zheng Z-J, Measah GA. Pulmonary hypertension surveillance - United States, 1980-2002. MMWR Surveill Summ. 2005;54:1-28.
6. Facts & Comparisons. Available at: http://www.factsandcomparisons. com. Accessed on March 7, 2010.
7. First Data Bank. Available at: http://www.rstdatabank.com. Accessed on March 22, 2010
8. Galiè N, Ghofrani HA, Toribicki A, et al; Sildena l Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildena l citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005; 353:2148-2157.
9. Oudiz RJ, Farber HW. Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am Heart J. 2009;157:625-635.
10. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation. 2006;114: 1417-1431
11. Taichman DB, McGoon MD, Harhay MO, et al. Wide variation in clinicians' assessment of New York Heart Association/World Health Organization functional class in patients with pulmonary arterial hypertension. Mayo Clin Proc. 2009;84:586-592.
12. Rubin LJ. Introduction: diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guide-lines. Chest. 2004;126:7S-10S.
13. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351:1655-1665.
14. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425-1436.
15. Chin KM, Rubin LJ. Pulmonary arterial hyper-tension. J Am Coll Cardiol. 2008;5:1527-1538.
16. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76-81.
17. Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111:3105-3111.
18. Galiè N, Brundage BH, Ghofrani HA, et al. Tadala l therapy for pulmonary arterial hyper-tension. Circulation. 2009;119:2894-2903.
19. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903.
20. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the Ambrisentan in Pulmonary Arterial Hypertension, Dou-ble-Bl ind, Placebo-Control led, Mult icenter, Ef cacy (ARIES) Randomized, study 1 and 2. Circulation. 2008;117:3010-3019.
21. Liu C, Chen J, Gao Y, Deng B, Liu K. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database of Systematic Reviews. 2009;Issue 3, Art. No.:CD004434.
22. Higenbottam T, Wheeldon D, Wells F, et al. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet. 1984;1:1046-1047.
23. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epopros-tenol). Results of a randomized trial. Ann Intern Med. 1990;112:485-491.
24. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: the Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996; 334:296-302.
25. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to scleroderma spectrum of disease: a randomized controlled trial. Ann Intern Med. 2000;132:425-434.
26. Sitbon O, Humbert M, Nunes H, et al. Long- term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40:780-788.
27. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106:1477-1482.
28. Simonneau G, Barst RJ, Galiè N, et al; Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary are rial hypertension: A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165:800-804.
29. Barst RJ, Galiè N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J. 2006;28:1195-1203. (Pubitemid 44883856)
30. Gomberg-Maitland M,Tapson VF, Benza R, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med. 2005;172:1586-1589. (Pubitemid 43076550)
31. Ty va so [ pack age inse r t ]. Re se a rch Tr i ang le Park, NC: United Therapeutics Corp.; 2009.
32. Ventavis [package insert]. South San Francisco, CA: Acetelion Pharmaceuticals US, Inc.; 2009.
33. McLaughlin VV, Oudiz RJ, Frost A. Random-ized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174; 1257-1263.
34. Ventetuolo CE, Benza R, Peacock AJ, Zamanian RT, Badesch DB, Kawut SM. Surrogate and combined endpoints in pulmonary arterial hypertension. Proc Am Thorac Soc. 2008;5:617-622.
35. McLaughlin VV, Badesch DB, Delcroix M, et al. Endpoints and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:S97-107.
36. Gomberg-Maitland M, Huo D, Benza RL, et al. Creation of a model comparing 6-minute walk test to metabolic equivalent in evaluating treatment effects in pulmonary arterial hypertension. J Heart Lung Transplant. 2007;26:732-738.
37. Gilbert C, Brown M, Cappelleri J, Carlsson M, McKenna SP. Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenal. Chest. 2009;135:137-142.
38. Macchia A, Marchioli R, Marsi R, et al. A meta analysis of trials of pulmonary hypertension: A clinical condition looking for drugs and research methodology. Am Heart J. 2007;153:1037-1047.
39. Gailè N, Manes A, Negro L, Palazzini M, Bacchi-Raggioni ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. 2009;30: 394-403.
40. Macchia A, Marchiloi R, Tognoni G, et al. Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed. Am Heart J. 2010;159: 245-257.
41. Wilkins MR, Paul GA, Strange JW, et al. Sildena l versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med. 2005;171:1292-1297.
42. Sastry BK, Narasimhan C, Reddy NK, Raju S. Clinical ef cacy of sildena l in primary pulmonary hypertension: a randomized, placebo controlled, double blinded, crossover study. J Am Coll Cardiol. 2004;43:1149-1153.
43. Keogh AM, McNeil KD, Wlodarczyk J, et al. Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan. J Heart Lung Transplant. 2007;26:181-187.
44. Galie N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46:529-535. (Pubitemid 41040298)
45. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322-329. (Pubitemid 34815354)
46. Mereles D, Ehlken N, Kreuscher S, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation. 2006;114:1482-1489.
47. Chen YF, Jowett S, Barton P, et al. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan, and sildena l for pulmonary arterial hypertension within their licensed indications: a systemic review and economic evaluation. Health Technol Assess. 2009; 13:1-320.
48. Narine L, Hague LK, Walker JH, et al. Costminimization analysis of treprostinil vs. epoprostenol as an alternate to oral therapy non-responders for the treatment of pulmonary arterial hypertension. Curr Med Res Opin. 2005;21:2007-2016.
49. Einarson TR, Granton JT, Vicente C, Walker JH, Engel G, Iskedjian M. Cost-effectiveness of treprostinil versus epoprostenol in patients with pulmonary arterial hypertension: a Canadian analysis. Can Respir J. 2005;12:419-425.
50. Highland K, Strange C, Mazur J, et al. Treatment of pulmonary arterial hypertension. A preliminary decision analysis. Chest. 2003;124:2087-2092.
51. Wlodarczyk JH, Cleland LG, Keogh AM, et al. Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia. Cost effectiveness and risk sharing. Pharmacoeconomics. 2006;24(9): 903-915.
52. Abraham T, Wu G, Vastey F, Rapp MS, Saad N, Balmir E. Role of combination therapy in the treatment of pulmonary arterial hypertension. Pharmacotherapy. 2010;30:390-404.